Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00106028 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children

A Phase 3 study of Osteogenesis Imperfecta, sponsored by Warner Chilcott.

Completed
Registry status
Phase 3
Development phase
143
Enrollment target
20
Study locations

NCT00106028: Completed Phase 3 study of Osteogenesis Imperfecta, sponsored by Warner Chilcott.

NCT00106028 is a Phase 3 study of Osteogenesis Imperfecta that has completed, run by Warner Chilcott. The registered enrollment target is 143 participants, roughly in line with the 150-participant average among 13 other Osteogenesis Imperfecta trials with a reported enrollment target. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00106028, a Phase 3 study of Osteogenesis Imperfecta, has completed, sponsored by Warner Chilcott.

COMPLETED
Registry status
Phase 3
Development phase
143 participants
Enrollment target
20
Study locations

Study Summary

Children with Osteogenesis Imperfecta (OI) have bone pain, low bone mass and fractures. There are no approved drugs for the treatment of OI in children, even though some intravenous (IV) bisphosphonates are used off-label in some countries. In a single dose, pharmacokinetic study, data showed that risedronate was well tolerated in 28 children with OI. This three year study will test the safety and efficacy of risedronate in the treatment of children with OI. For the first year, patients will be randomized to the risedronate and placebo groups in a 2:1 ratio. For the second and third years of the study, all patients will receive risedronate.

Primary Outcome

Lumbar Spine Bone Mineral Density (BMD) measured by dual-energy x-ray absorptiometry (DXA)and read by central reader. Duplicate scans obtained at screening and Month 12.

Conditions Studied

Osteogenesis Imperfecta

Interventions

  • DRUG Placebo
  • DRUG risedronate sodium (Actonel)

Study Locations (20)

Other

  • Princess Margaret Hospital for Children - Perth
  • Cliniques Universitaires Saint Luc - Brussels
  • Pontificia Universidad Catolica de Chile - Santiago
  • Osteocentrum, II. Interní klinika, Fakultní nemocnice Plzeň-Bory - Pilsen
  • Hospital for Children and Adolescents - Helsinki
  • Klinikum und Poliklinik für Kinderheilkunde der Universität zu Köln - Cologne
  • 2nd Department of Pediatrics, Semmelwies University, Faculty of Medicine - Budapest
  • Rheumatologic Rehabilitation Unit of the University of Verona - Valeggio sul Mincio
  • Zaklad Biochemii i Medycyny Doswiadczalnej (Biochemisty Dept, Institute "Monument-Children Health Centre" - Warzawa-Międzylesie
  • Hospital Sant Joan de Deu - Barcelona
  • Bristol Royal Hospital for Children, - Bristol

Florida

  • Miami Children's Hospital - Miami

Nebraska

  • University of Nebraska Medical Center, Children's Hospital - Omaha

New York

  • Hospital for Special Surgery - New York

Ohio

  • Wright State University BioMedical Imaging Laboratory and Miami Valley Hospital - Dayton

Oregon

  • Oregon Health & Science University - Portland

New South Wales

  • The Children's Hospital at Westmead - Westmead

Gauteng

  • Little Company of Mary Hospital - Pretoria

Trial Details

FieldValue
Enrollment Target 143 participants
Start Date 2004-11
Est. Completion 2010-03
Phase Phase 3
Warner Chilcott

53 total trials

What the finished NCT00106028 record still lists

NCT00106028 is an interventional study that assigns participants to a tested intervention. The registered 143 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 150-participant average among 13 other Osteogenesis Imperfecta trials with a reported enrollment target.

The record links to 1 condition, with Osteogenesis Imperfecta appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00106028 names 20 study sites across 10 states, led by Other, Florida, Nebraska.

Frequently Asked Questions

What is clinical trial NCT00106028 about?

NCT00106028 is a clinical study titled "Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children". Children with Osteogenesis Imperfecta (OI) have bone pain, low bone mass and fractures. There are no approved drugs for the treatment of OI in children, even though some intravenous (IV) bisphosphonates are used off-label in some countries. In a single dose, pharmacokinetic study, data showed that r...

What is the current status of trial NCT00106028?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 143 participants. The study started on 2004-11. Estimated completion is 2010-03.

What conditions does trial NCT00106028 study?

This clinical trial studies the following conditions: Osteogenesis Imperfecta.

What interventions are being tested in trial NCT00106028?

The interventions under investigation include: Placebo (DRUG), risedronate sodium (Actonel) (DRUG).

Who is sponsoring clinical trial NCT00106028?

This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00106028 being conducted?

This trial has 20 study locations across Florida, Nebraska, New York, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Osteogenesis Imperfecta

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00106028's enrollment target sits among peer trials

143 4th of 13 higher than 10 of 13 other Osteogenesis Imperfecta trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Osteogenesis Imperfecta trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01861106 · 144 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

  • NCT03482245 · 144 participants · NA

    The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

  • NCT03504683 · 144 participants · NA

    MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes

  • NCT03905603 · 144 participants · Early Phase 1

    Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00106028, the US trial registry maintained by the National Library of Medicine. NCT00106028 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.